COVID-19 Update: See the latest on our visitor policy here. Learn More
Cancer Type: Neurologic Oncology
Study Type: Treatment
NCT#: NCT04471844
Phase: N/A
Principal Investigator: Yu, Hsiang-Hsuan (Michael)
A Pivotal Randomized, Open-Label Study Of OPTUNE(R)(TTFIELDS, 200KHZ) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Primary Objective: To determine if TTFields treatment at 200 kHz to the brain concomitantly with RT and TMZ in the treatment of GBM patients prolongs the overall survival of patients, compared to RT and TMZ treatments followed by TTFields and maintenance TMZ. Secondary Objectives: To determine if TTFields at 200 kHz to the brain concomitant with RT+ TMZ in the treatment of newly diagnosed GBM patients prolongs the progression-free survival of patients, compared to RT + TMZ followed by TTFields + maintenance TMZ To determine if TTFields at 200 kHz to the brain concomitant with RT+ TMZ in the treatment of newly diagnosed GBM patients increases the 1- and 2-year survival rates of patients, compared to RT + TMZ followed by TTFields + maintenance TMZ. To determine if TTFields at 200 kHz to the brain concomitant with RT TMZ in the treatment of newly diagnosed GBM patients improves the overall radiological response rate of patients, compared to RT + TMZ followed by TTFields + maintenance TMZ. To determine if TTFields at 200 kHz to the brain concomitant with RT + TMZ in the treatment of newly diagnosed GBM patients prolongs the next progression-free survival (PFS2) of patients, compared to RT + TMZ followed by TTFields + maintenance TMZ. To determine if TTFields at 200 kHz to the brain concomitant with RT+ TMZ in the treatment of newly diagnosed GBM patients increases the progression-free survival rate at 6 and 12 months, compared to RT + TMZ followed by TTFields + maintenance TMZ. To compare severity and frequency of adverse events of TTFields at 200 kHz to the brain concomitant with RT + TMZ in the treatment of newly diagnosed GBM patients to that of treatment with RT + TMZ followed by TTFields + maintenance TMZ. To describe potential pathological changes in GBM tumors following the treatment of patients treated with TTFields at 200 kHz to the brain concomitant with RT + TMZ followed by TTFields + maintenance TMZ. To compare Quality of Life using the EORTC QLQ C30 (with BN20 module) of TTFields at 200 kHz to the brain concomitant with RT + TMZ in the treatment of newly diagnosed GBM patients to that of treatment with RT + TMZ followed by TTFields + maintenance TMZ. To explore if TTFields at 200 kHz prolongs overall survival in a dose dependent-manner, i.e. to explore the possible connection between higher doses of TTFields at the tumor bed and longer patient survival. NANO scale: To compare neurologic function of TTFields at 200 kHz to the brain concurrent with RT + TMZ in the treatment of newly diagnosed GBM patients to the of treatment with RT + TMZ followed by TTFields + maintenance TMZ using the NANO scale.
Chemotherapy (NOS); Radiotherapy
TTFields (); Temodal (Temozolomide); Temozolomide ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday